The Temple Lung Center was designated as a member of the Bronchiectasis and Nontuberculous Mycobacterial (NTM) Care Center Network, according to a March 24 announcement. The designation recognizes the center’s expertise in treating bronchiectasis, a chronic lung condition that makes breathing difficult due to damaged airways.
This recognition is significant for patients with bronchiectasis, as it ensures access to specialized care and resources at one of the nation’s leading treatment centers. The network was established to improve timely diagnosis and provide educational resources for those affected by chronic lung diseases.
“Bronchiectasis is a condition that affects so many people: about 500,000 in the United States alone,” said Daniel A. Salerno, MD, MS, Professor of Thoracic Medicine & Surgery at the Lewis Katz School of Medicine at Temple University. “The Temple Lung Center is already a national and worldwide leader in treating chronic lung conditions, and our partnership with the Bronchiectasis and NTM Care Center Network will provide essential resources as we look to care for even more bronchiectasis patients.”
As part of this new role within the network, patients at Temple will have opportunities to participate in clinical trials beyond the more than 50 studies already underway at the center. They will also gain access to an expanded research database through this partnership.
“This is a very exciting time for bronchiectasis treatment,” Salerno said. “Last August, the FDA approved the first medication specifically for non-cystic fibrosis bronchiectasis, and we’ve been able to prescribe it to some of our patients. There are so many treatments on the horizon that can really make a difference, and thanks to this partnership, we’ll be at the forefront of using new therapies to provide much-needed relief.”
The new designation positions Temple Lung Center among leading institutions working toward improved outcomes for individuals living with bronchiectasis.
